ALIM - Alimera Sciences Inc Stock Price, Fair Value and News

$5.54

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALIM Price Action

Last 7 days

-0.4%

Last 30 days

-0.9%

Last 90 days

74.8%

Trailing 12 Months

63.4%

ALIM RSI Chart

ALIM Valuation

Market Cap

301.3M

Price/Earnings (Trailing)

-20.5

Price/Sales (Trailing)

3.02

EV/EBITDA

25.52

Price/Free Cashflow

-51.79

ALIM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALIM Fundamentals

ALIM Revenue

Revenue (TTM)

99.7M

Rev. Growth (Yr)

53.95%

Rev. Growth (Qtr)

17.34%

ALIM Earnings

Earnings (TTM)

-14.7M

Earnings Growth (Yr)

66.99%

Earnings Growth (Qtr)

47.03%

ALIM Profitability

EBT Margin

-14.76%

Return on Equity

-37.89%

Return on Assets

-9.77%

Free Cashflow Yield

-1.93%

ALIM Investor Care

Shares Dilution (1Y)

517.88%

Diluted EPS (TTM)

-0.74

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	90.2M	99.7M	0	0
2023	55.8M	58.7M	68.5M	80.8M
2022	59.7M	52.6M	54.1M	54.1M
2021	47.5M	59.2M	58.8M	59.0M
2020	55.6M	54.8M	54.4M	50.8M
2019	49.9M	50.0M	51.7M	53.9M
2018	38.9M	39.3M	40.6M	46.6M
2017	35.1M	36.0M	37.4M	35.9M
2016	24.3M	28.1M	29.5M	34.3M
2015	10.3M	13.9M	18.4M	22.4M
2014	3.5M	5.1M	6.8M	8.4M
2013	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

CEO	Mr. Richard S. Eiswirth Jr.
WEBSITE	https://alimerasciences.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	150

Alimera Sciences Inc Frequently Asked Questions

What is the ticker symbol for Alimera Sciences Inc? What does ALIM stand for in stocks?

ALIM is the stock ticker symbol of Alimera Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alimera Sciences Inc (ALIM)?

As of Wed Sep 18 2024, market cap of Alimera Sciences Inc is 301.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALIM stock?

You can check ALIM's fair value in chart for subscribers.

Is Alimera Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALIM is over valued or under valued. Whether Alimera Sciences Inc is cheap or expensive depends on the assumptions which impact Alimera Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALIM.

What is Alimera Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, ALIM's PE ratio (Price to Earnings) is -20.5 and Price to Sales (PS) ratio is 3.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alimera Sciences Inc's stock?

In the past 10 years, Alimera Sciences Inc has provided -0.231 (multiply by 100 for percentage) rate of return.